The BBB infiltrating drugs market is projected to develop at an annualized pace of ~154%, till 2030

Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 400+ page report, which features 145+ figures and 205+ tables, please visit Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

Key Market Insights

  • More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
  • Majority of drug candidates are currently in the early stages of development, and are intended for the treatment of neurological conditions; a large proportion of the existing pipeline molecules are biologics
  • In order to achieve a competitive edge, several technology developers are presently focusing on the integration of advanced technical features into their proprietary drug development / delivery platforms
  • An assessment of 240+ drug developers, focused on Parkinson’s and Alzheimer’s diseases, revealed that many such firms are likely to partner with technology providers in order to leverage their BBB penetration expertise
  • Over the years, more than 16,700 patents related to BBB technologies have been filed / granted to various industry and non-industry players, indicating the pace of R&D activity in this burgeoning field of research
  • Foreseeing a lucrative future, several private and public investors have invested close to USD 1 billion, across more than 70 funding instances
  • Revenues generated from the sales of BBB penetrating drugs are anticipated to be well distributed across different types of molecules, target disease indications and various global regions over time
  • In the near-term, the opportunity is likely to be driven by licensing activity driven by the capability of leading BBB penetrating technologies to successfully facilitate drug delivery into the brain

For more information, please visit

Table of Contents


1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines



3.1. Chapter Overview

3.2. Structure of the Human Brain

3.3. Global Burden on Neurological Disorders and Impact of Coronavirus Disease (COVID-19)

3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)

3.4.1. Invasive Techniques Systemic Administration of Therapeutics Direct Administration of Therapeutics Intracerebral Devices and Implants

3.4.2. Non-Invasive Techniques / Approaches Liposomes Exosomes Prodrugs Nanoparticles and Microspheres Novel Formulations and Conjugates

3.4.3. Chemical Delivery Systems

3.5. Blood-Brain Barrier (BBB)

3.5.1. Key Historical Milestones

3.5.2. Structure and Key Components

3.5.3. Key Functions

3.6. Strategies for Drug Delivery across the BBB

3.6.1. Increasing Permeability by Temporary Disruption of the BBB

3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB

3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery

3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies

3.8.1. Emerging Focus Areas

3.8.2. Key Historical Trends

3.8.3. Geographical Activity

3.9. Concluding Remarks


4.1. Chapter Overview

4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape

4.2.1. Analysis by Status of Development

4.2.2. Analysis by Underlying Principle

4.2.3. Analysis by Compatible Pharmacological Molecule(s)

4.2.4. Analysis by Target Receptor(s)

4.2.5. Analysis by Target Disease Indication(s)

4.2.6. Analysis by Patent Availability

4.2.7. Analysis by Licensing Activity

4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape

4.3.1. Analysis by Year of Establishment

4.3.2. Analysis by Company Size

4.3.3. Analysis by Location of Headquarters


5.1. Chapter Overview

5.2. BBB Penetrating Drugs: Development Pipeline

5.2.1. Analysis by Phase of Development

5.2.2. Analysis by Type of Molecule

5.2.3. Analysis by Affiliated BBB Penetration Technology

5.2.4. Analysis by Route of Administration

5.2.5. Analysis by Target Disease Indication(s)

5.2.6. Analysis by Therapeutic Area(s)

5.3. BBB Penetrating Drugs: Additional Information

5.4. BBB Penetrating Drug Developers: Overall Market Landscape

5.4.1. Analysis by Year of Establishment

5.4.2. Analysis by Company Size

5.4.3. Analysis by Location of Headquarters

5.4.4. Leading Drug Developers: Analysis by Number of Drugs

5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size

5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications

5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Facebook –

LinkedIn – Twitter –